Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension (15mg.).

NCT00211471 is registered in ClinicalTrials.gov with Manhattan Eye, Ear & Throat Hospital as lead sponsor.

NCT NCT00211471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00211471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension (15mg.).
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2002
Completion date
May 31, 2007
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central retinal vein occlusion, chronic inflammation, infectious diseases, severe diabetic retinopathy